Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL.
Dorshkind
Kenneth
K
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA. kdorshki@mednet.ucla.edu
Witte
Owen N
ON
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006412:Hematopoietic Stem Cells / Q000502:physiology*; D006801:Humans; D000068877:Imatinib Mesylate; D051379:Mice; D008954:Models, Biological; D014411:Neoplastic Stem Cells / Q000473:pathology*; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000178:diet therapy* / Q000473:pathology*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate